EA007474B1 - Способ индукции дифференцировки клеток - Google Patents
Способ индукции дифференцировки клеток Download PDFInfo
- Publication number
- EA007474B1 EA007474B1 EA200401105A EA200401105A EA007474B1 EA 007474 B1 EA007474 B1 EA 007474B1 EA 200401105 A EA200401105 A EA 200401105A EA 200401105 A EA200401105 A EA 200401105A EA 007474 B1 EA007474 B1 EA 007474B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dicarbamine
- cells
- group
- chemotherapy
- general formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 22
- 230000024245 cell differentiation Effects 0.000 title claims abstract description 17
- 230000006698 induction Effects 0.000 title claims abstract description 10
- 238000002512 chemotherapy Methods 0.000 claims abstract description 83
- 201000001441 melanoma Diseases 0.000 claims abstract description 47
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 40
- 230000012010 growth Effects 0.000 claims abstract description 22
- 231100000226 haematotoxicity Toxicity 0.000 claims abstract description 21
- 238000009169 immunotherapy Methods 0.000 claims abstract description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 239000004215 Carbon black (E152) Substances 0.000 claims description 13
- 125000003277 amino group Chemical group 0.000 claims description 13
- 229930195733 hydrocarbon Natural products 0.000 claims description 13
- 229940079322 interferon Drugs 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 102000014150 Interferons Human genes 0.000 claims description 7
- 108010050904 Interferons Proteins 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- -1 cyclic imide Chemical class 0.000 claims description 5
- 206010061188 Haematotoxicity Diseases 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 2
- 230000000771 oncological effect Effects 0.000 abstract description 2
- 230000003019 stabilising effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 109
- 206010028980 Neoplasm Diseases 0.000 description 68
- 241000699670 Mus sp. Species 0.000 description 52
- 230000000694 effects Effects 0.000 description 44
- 230000004069 differentiation Effects 0.000 description 36
- 238000011282 treatment Methods 0.000 description 35
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 34
- 229960004397 cyclophosphamide Drugs 0.000 description 34
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 30
- 229960004562 carboplatin Drugs 0.000 description 30
- 210000004881 tumor cell Anatomy 0.000 description 26
- 210000000265 leukocyte Anatomy 0.000 description 25
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 210000001185 bone marrow Anatomy 0.000 description 20
- 210000005259 peripheral blood Anatomy 0.000 description 19
- 239000011886 peripheral blood Substances 0.000 description 19
- 230000004614 tumor growth Effects 0.000 description 19
- 210000000805 cytoplasm Anatomy 0.000 description 18
- 230000006907 apoptotic process Effects 0.000 description 17
- 108010047761 Interferon-alpha Proteins 0.000 description 16
- 102000006992 Interferon-alpha Human genes 0.000 description 16
- 239000000824 cytostatic agent Substances 0.000 description 16
- 210000004940 nucleus Anatomy 0.000 description 16
- 230000001085 cytostatic effect Effects 0.000 description 15
- 210000003714 granulocyte Anatomy 0.000 description 14
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 14
- 210000001772 blood platelet Anatomy 0.000 description 13
- 229960004316 cisplatin Drugs 0.000 description 13
- 230000007423 decrease Effects 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 210000000440 neutrophil Anatomy 0.000 description 13
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 12
- 230000017074 necrotic cell death Effects 0.000 description 12
- 208000004235 neutropenia Diseases 0.000 description 12
- 206010033128 Ovarian cancer Diseases 0.000 description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000002062 proliferating effect Effects 0.000 description 11
- 108010078049 Interferon alpha-2 Proteins 0.000 description 10
- 238000009534 blood test Methods 0.000 description 10
- 238000011081 inoculation Methods 0.000 description 10
- 238000011269 treatment regimen Methods 0.000 description 10
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 206010049466 Erythroblastosis Diseases 0.000 description 8
- 210000003969 blast cell Anatomy 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000000411 inducer Substances 0.000 description 8
- 210000002780 melanosome Anatomy 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 206010043554 thrombocytopenia Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 231100000433 cytotoxic Toxicity 0.000 description 7
- 230000001472 cytotoxic effect Effects 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108010077544 Chromatin Proteins 0.000 description 6
- 208000001382 Experimental Melanoma Diseases 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000001493 electron microscopy Methods 0.000 description 6
- 201000002364 leukopenia Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 210000003887 myelocyte Anatomy 0.000 description 5
- 210000003705 ribosome Anatomy 0.000 description 5
- 238000003307 slaughter Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- 108010034791 Heterochromatin Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940044683 chemotherapy drug Drugs 0.000 description 4
- 210000000224 granular leucocyte Anatomy 0.000 description 4
- 230000002012 hematotoxic effect Effects 0.000 description 4
- 210000004458 heterochromatin Anatomy 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 210000003924 normoblast Anatomy 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 210000004765 promyelocyte Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Natural products NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 231100001022 leukopenia Toxicity 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 231100000065 noncytotoxic Toxicity 0.000 description 3
- 230000002020 noncytotoxic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BADMGRJDJPQBLS-UNTFVMJOSA-N 1-methyl-1-nitroso-3-[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]urea Chemical compound O=NN(C)C(=O)N[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O BADMGRJDJPQBLS-UNTFVMJOSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000012568 clinical material Substances 0.000 description 2
- 238000009096 combination chemotherapy Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 238000012735 histological processing Methods 0.000 description 2
- 230000000215 hyperchromic effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 2
- 239000012285 osmium tetroxide Substances 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003935 rough endoplasmic reticulum Anatomy 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229950003937 tolonium Drugs 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- XDHJBIYJRNFDKS-IBGZPJMESA-N 1-[(4-methoxyphenyl)methyl]-5-[(2s)-2-(pyridin-3-yloxymethyl)pyrrolidin-1-yl]sulfonylindole-2,3-dione Chemical compound C1=CC(OC)=CC=C1CN1C2=CC=C(S(=O)(=O)N3[C@@H](CCC3)COC=3C=NC=CC=3)C=C2C(=O)C1=O XDHJBIYJRNFDKS-IBGZPJMESA-N 0.000 description 1
- NOVZFMNCTCKLPF-UHFFFAOYSA-N 2,5-bis(aziridin-1-yl)-3,6-dipropoxycyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(OCCC)=C(N2CC2)C(=O)C(OCCC)=C1N1CC1 NOVZFMNCTCKLPF-UHFFFAOYSA-N 0.000 description 1
- SYEWHONLFGZGLK-UHFFFAOYSA-N 2-[1,3-bis(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COCC(OCC1OC1)COCC1CO1 SYEWHONLFGZGLK-UHFFFAOYSA-N 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical class OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000141 anti-hypoxic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 101150002418 cpi-2 gene Proteins 0.000 description 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003039 myelosuppressive effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- UDEJEOLNSNYQSX-UHFFFAOYSA-J tetrasodium;2,4,6,8-tetraoxido-1,3,5,7,2$l^{5},4$l^{5},6$l^{5},8$l^{5}-tetraoxatetraphosphocane 2,4,6,8-tetraoxide Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P1(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)O1 UDEJEOLNSNYQSX-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2002105392/14A RU2217196C2 (ru) | 2002-02-28 | 2002-02-28 | Способ индукции дифференцировки клеток |
| PCT/RU2003/000072 WO2003072124A1 (en) | 2002-02-28 | 2003-02-28 | Induction method for cell differentiation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200401105A1 EA200401105A1 (ru) | 2004-12-30 |
| EA007474B1 true EA007474B1 (ru) | 2006-10-27 |
Family
ID=27764932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200401105A EA007474B1 (ru) | 2002-02-28 | 2003-02-28 | Способ индукции дифференцировки клеток |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7759313B2 (enExample) |
| EP (1) | EP1491206B9 (enExample) |
| JP (1) | JP4711626B2 (enExample) |
| CN (1) | CN1649612B (enExample) |
| AT (1) | ATE488234T1 (enExample) |
| AU (1) | AU2003235538A1 (enExample) |
| CY (1) | CY1111265T1 (enExample) |
| DE (1) | DE60334978D1 (enExample) |
| DK (1) | DK1491206T3 (enExample) |
| EA (1) | EA007474B1 (enExample) |
| ES (1) | ES2356308T3 (enExample) |
| HK (1) | HK1079990B (enExample) |
| IL (3) | IL163763A0 (enExample) |
| PT (1) | PT1491206E (enExample) |
| RU (1) | RU2217196C2 (enExample) |
| SI (1) | SI1491206T1 (enExample) |
| UA (1) | UA85039C2 (enExample) |
| WO (1) | WO2003072124A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015137846A1 (ru) * | 2014-03-12 | 2015-09-17 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы их получения и применение |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MC200060A1 (fr) | 2002-10-04 | 2003-05-28 | M Exsymol Sa | Produit de couplage entre la tryptamine et un alpha-aminoacide son procédé de préparation et son application dans le domaine de la neuro-cosmétique |
| RU2335495C2 (ru) * | 2005-06-15 | 2008-10-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | N-ацильные производные аминокислот, их фармацевтически приемлевые соли, фармацевтическая композиция и применение в качестве гиполипидемических средств |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способы получения n-ацильных производных аминокислот (варианты) |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств |
| RU2373934C1 (ru) * | 2008-03-19 | 2009-11-27 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств |
| RU2359030C1 (ru) * | 2008-03-19 | 2009-06-20 | Общество С Ограниченной Ответственностью "Лаборатория Клеточных Технологий" | Способ получения эндотелиальных клеток из эмбриональных стволовых клеток человека (варианты) |
| JP5370957B2 (ja) | 2008-08-20 | 2013-12-18 | 学校法人日本大学 | アポトーシス抑制剤 |
| KR101414942B1 (ko) * | 2010-10-22 | 2014-07-04 | 코럼 아이엔씨 | 멜라닌 생성을 억제하는 글리신 유도체 및 그 미백 조성물 |
| CN104257515B (zh) * | 2010-10-22 | 2017-05-03 | 新钰生技股份有限公司 | 具有抑制黑色素生成的甘胺酸衍生物及使用其的美白组成物 |
| UA115431C2 (uk) * | 2011-10-11 | 2017-11-10 | Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" | Застосування глутарилгістаміну для лікування захворювань дихальних шляхів |
| CN103382179A (zh) * | 2013-06-05 | 2013-11-06 | 四川百利药业有限责任公司 | 英加韦林的多晶型物及其制备方法 |
| SG11202102821QA (en) * | 2018-09-25 | 2021-04-29 | Myelo Therapeutics Gmbh | Imidazolyl ethanamide pentandioic acid for use in therapy of symptoms related to exposure to lethal radiation |
| RU2726119C1 (ru) * | 2019-11-22 | 2020-07-09 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Новые производные полиолов, их применение, фармацевтическая композиция на их основе |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU96110217A (ru) * | 1993-10-29 | 1998-08-10 | Дзе Транстиз оф Бостон Юниверсити | Физиологически стабильные композиции масляной кислоты, соли и производные масляной кислоты в качестве анти-неопластических средств |
| RU2141483C1 (ru) * | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6016926A (ja) * | 1983-07-06 | 1985-01-28 | Kaneshiro Nagai | 抗腫瘍剤 |
| JPS6016934A (ja) * | 1983-07-06 | 1985-01-28 | Kaneshiro Nagai | 抗腫瘍剤 |
| US4816442A (en) * | 1986-11-07 | 1989-03-28 | Collagen Corporation | Method of inhibiting tumor growth sensitive to CIF-βtreatment |
| JPS6442430A (en) * | 1987-08-11 | 1989-02-14 | Nippon Univ | Side effect remover for chemotherapeutic agent |
| US5350836A (en) * | 1989-10-12 | 1994-09-27 | Ohio University | Growth hormone antagonists |
| JPH0585942A (ja) | 1991-02-26 | 1993-04-06 | Denki Kagaku Kogyo Kk | インターフエロン−ヒアルロン酸及び／又はその塩の結合体 |
| CA2108584C (en) * | 1992-10-27 | 1998-11-24 | James B. Doherty | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| GB9308695D0 (en) * | 1993-04-27 | 1993-06-09 | Celltech Ltd | Peptidyl derivatives |
| IL110296A (en) * | 1993-07-16 | 1999-12-31 | Smithkline Beecham Corp | Imidazole compounds process for their preparation and pharmaceutical compositions containing them |
| AU696167B2 (en) | 1993-10-29 | 1998-09-03 | Trustees Of Boston University | Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents |
| JP3517274B2 (ja) * | 1994-05-20 | 2004-04-12 | 株式会社ナリス化粧品 | 皮膚組成物 |
| RU2120298C1 (ru) * | 1995-11-28 | 1998-10-20 | Товарищество с ограниченной ответственностью "Верта" | Иммуностимулятор и препарат на его основе |
| FR2762315B1 (fr) * | 1997-04-22 | 1999-05-28 | Logeais Labor Jacques | Derives d'amino-acides inhibiteurs des metalloproteases de la matrice extracellulaire et de la liberation du tnf alpha |
| DE69840451D1 (de) * | 1997-11-07 | 2009-02-26 | Mayo Foundation | Interferon-immuntherapie mit niedriger dosis |
| US6838436B1 (en) * | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
| AU768269B2 (en) * | 1998-10-02 | 2003-12-04 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Apoptosis inducing agents and methods |
-
2002
- 2002-02-28 RU RU2002105392/14A patent/RU2217196C2/ru not_active IP Right Cessation
-
2003
- 2003-02-28 EP EP03743087A patent/EP1491206B9/en not_active Expired - Lifetime
- 2003-02-28 UA UA20040907835A patent/UA85039C2/uk unknown
- 2003-02-28 CN CN038094959A patent/CN1649612B/zh not_active Expired - Lifetime
- 2003-02-28 DK DK03743087.3T patent/DK1491206T3/da active
- 2003-02-28 AT AT03743087T patent/ATE488234T1/de active
- 2003-02-28 EA EA200401105A patent/EA007474B1/ru unknown
- 2003-02-28 HK HK06100072.5A patent/HK1079990B/zh not_active IP Right Cessation
- 2003-02-28 AU AU2003235538A patent/AU2003235538A1/en not_active Abandoned
- 2003-02-28 DE DE60334978T patent/DE60334978D1/de not_active Expired - Lifetime
- 2003-02-28 IL IL16376303A patent/IL163763A0/xx unknown
- 2003-02-28 ES ES03743087T patent/ES2356308T3/es not_active Expired - Lifetime
- 2003-02-28 PT PT03743087T patent/PT1491206E/pt unknown
- 2003-02-28 US US10/505,976 patent/US7759313B2/en not_active Expired - Lifetime
- 2003-02-28 WO PCT/RU2003/000072 patent/WO2003072124A1/ru not_active Ceased
- 2003-02-28 JP JP2003570868A patent/JP4711626B2/ja not_active Expired - Lifetime
- 2003-02-28 SI SI200331938T patent/SI1491206T1/sl unknown
-
2004
- 2004-08-26 IL IL163763A patent/IL163763A/en active IP Right Grant
-
2010
- 2010-11-30 IL IL209653A patent/IL209653A0/en unknown
-
2011
- 2011-02-09 CY CY20111100154T patent/CY1111265T1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU96110217A (ru) * | 1993-10-29 | 1998-08-10 | Дзе Транстиз оф Бостон Юниверсити | Физиологически стабильные композиции масляной кислоты, соли и производные масляной кислоты в качестве анти-неопластических средств |
| RU2141483C1 (ru) * | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
Non-Patent Citations (1)
| Title |
|---|
| KULESZ-MARTIN MF et al.: Differentiation and tumor response to retinobenzoic acid re-80 in a malignant conversion model II Cancer Detect Prev 1995; 19(4): 355-66, abstr. PubMed (http://www/ncbi.nlm.nih.gov/ entrez/query.fcgi) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015137846A1 (ru) * | 2014-03-12 | 2015-09-17 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы их получения и применение |
| RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| EA035439B1 (ru) * | 2014-03-12 | 2020-06-15 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидное соединение и его применение в качестве средства для лечения и профилактики заболеваний, вызываемых рнк- и/или днк-содержащими вирусами, и сопутствующих заболеваний |
| EA035545B1 (ru) * | 2014-03-12 | 2020-07-06 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк- и/или днк-содержащими вирусами, и сопутствующих заболеваний |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1491206B9 (en) | 2011-03-09 |
| WO2003072124A1 (en) | 2003-09-04 |
| CN1649612A (zh) | 2005-08-03 |
| HK1079990B (zh) | 2011-12-09 |
| HK1079990A1 (en) | 2006-04-21 |
| US20050180953A1 (en) | 2005-08-18 |
| EA200401105A1 (ru) | 2004-12-30 |
| JP2005532269A (ja) | 2005-10-27 |
| AU2003235538A1 (en) | 2003-09-09 |
| PT1491206E (pt) | 2011-02-11 |
| EP1491206A4 (en) | 2006-01-11 |
| US7759313B2 (en) | 2010-07-20 |
| ATE488234T1 (de) | 2010-12-15 |
| UA85039C2 (uk) | 2008-12-25 |
| EP1491206A1 (en) | 2004-12-29 |
| JP4711626B2 (ja) | 2011-06-29 |
| IL209653A0 (en) | 2011-02-28 |
| RU2217196C2 (ru) | 2003-11-27 |
| DE60334978D1 (de) | 2010-12-30 |
| DK1491206T3 (da) | 2011-03-14 |
| SI1491206T1 (sl) | 2011-03-31 |
| EP1491206B1 (en) | 2010-11-17 |
| ES2356308T3 (es) | 2011-04-06 |
| IL163763A (en) | 2011-12-29 |
| IL163763A0 (en) | 2005-12-18 |
| CY1111265T1 (el) | 2015-08-05 |
| CN1649612B (zh) | 2011-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1100589B1 (en) | Use of propionyl l-carnitine and acetyl l-carnitine in the preparation of medicaments with anticancer activity | |
| EA007474B1 (ru) | Способ индукции дифференцировки клеток | |
| NO334085B1 (no) | Anvendelse av fettsyrer med middels kjedelengde, glyserider og analoger for fremstilling av et medikament for stimulering av erytropoese | |
| JP2845622B2 (ja) | インターロイキン―２とヒスタミン、その類似体又はｈ▲下２▼―受容体アゴニストを含む抗腫瘍性製剤 | |
| KR100424503B1 (ko) | 암전이억제제 | |
| JP4520443B2 (ja) | グルタチオンアナログの代謝的効果 | |
| EP0923371B1 (en) | Pharmaceutical compositions comprising tyrphostins | |
| CN116726021A (zh) | 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途 | |
| AU2007273809A1 (en) | Combination methods of treating cancer | |
| RU2396952C2 (ru) | Комбинация, включающая комбретастатин и противораковые средства | |
| KR100459484B1 (ko) | 엔-아세틸 파이토스핑고신과 다이메틸 파이토스핑고신을유효 성분으로 포함하는 방사선 치료 민감제 조성물 | |
| KR20070063507A (ko) | 면역조절작용과 화학방어활성을 가진 치환된 퓨리닐 유도체및 단독 또는 중쇄 길이 지방산이나 글리세리드와의 혼합사용 | |
| RU2725135C1 (ru) | Гемопротекторное средство | |
| KR20120139311A (ko) | 림프 혈관 생성 조성물 | |
| JP2021511358A (ja) | 第一鉄アミノ酸粒子を含む組成物、および膵臓関連疾患の治療または改善のための薬剤製造におけるその組成物の使用 | |
| RU2696586C1 (ru) | Гемопротекторное средство | |
| YOKOMORI et al. | Synchronization effect of cis-dichlorodiammineplatinum on a human neuroblastoma in vitro and in nude mice | |
| JPH04182427A (ja) | キサントシリンｘジメチルエーテルを含有する抗腫瘍剤 | |
| KATSURA et al. | Human Neoplastic Disease In Cancer Chemo-therapy Studies 1, 2, 3 | |
| TW202005664A (zh) | 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途 | |
| JPH09301991A (ja) | がん転移抑制剤 | |
| AKAISHI | Correlation Between Yoshida Sarcoma and Human Neoplastic Disease In Cancer Chemo | |
| JPH07309758A (ja) | 癌細胞転移阻害剤 | |
| MXPA99001505A (en) | Pharmaceutical compositions comprising tyrphostins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Registration of transfer of a eurasian patent by assignment |